Despite the fact that EGFR-TKIs in advanced disease did not allow achieving a curative intent so far, the benefit observed in overall response rate (ORR), PFS, and OS set the stage for a promising activity of these small molecules in EGFR mutant early stage NSCLC, including the neoadjuvant setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.